BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 9155045)

  • 1. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
    Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
    Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival.
    Korkolopoulou P; Kouzelis K; Christodoulou P; Papanikolaou A; Thomas-Tsagli E
    Acta Neuropathol; 1998 Jun; 95(6):617-24. PubMed ID: 9650754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of P21 WAF1/CIP1 in human astrocytomas in correlating with P53, MDM2, and cellular proliferation index].
    Xu QZ; Liu F; Lu DH; Yu SZ; Yang H
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):341-5. PubMed ID: 12940073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours.
    Jaros E; Perry RH; Adam L; Kelly PJ; Crawford PJ; Kalbag RM; Mendelow AD; Sengupta RP; Pearson AD
    Br J Cancer; 1992 Aug; 66(2):373-85. PubMed ID: 1503912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of proliferating cell nuclear antigen (PCNA), AgNORs and P53 in non-Hodgkin's lymphomas.
    Korkolopoulou P; Angelopoulou MK; Kontopidou F; Tsengas A; Patsouris E; Kittas C; Pangalis GA
    Leuk Lymphoma; 1998 Aug; 30(5-6):625-36. PubMed ID: 9711925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of p53, PCNA, Ki-67, MDM2 and AgNOR in oral peripheral and central giant cell lesions.
    Souza PE; Mesquita RA; Gomez RS
    Oral Dis; 2000 Jan; 6(1):35-9. PubMed ID: 10673786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
    Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in astrocytic gliomas and their correlation to cell proliferation.
    Dietzmann K; von Bossanyi P; Sallaba J; Kirches E; Synowitz HJ; Warich-Kirches M
    Gen Diagn Pathol; 1996 May; 141(5-6):339-44. PubMed ID: 8780933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours.
    Häyry V; Tynninen O; Haapasalo HK; Wölfer J; Paulus W; Hasselblatt M; Sariola H; Paetau A; Sarna S; Niemelä M; Wartiovaara K; Nupponen NN
    Neuropathol Appl Neurobiol; 2008 Oct; 34(5):555-63. PubMed ID: 18346113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of PCNA, Ki67, AgNOR and p53 expression in brain glial tumors].
    Berny W; Weiser A; Markowska-Woyciechowska A; Jarmundowicz W; Zub W; Załuski R
    Neurol Neurochir Pol; 2004; 38(6):457-63. PubMed ID: 15654669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
    Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
    Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival.
    Ehrmann J; Kolár Z; Vojtĕsek B; Kala M; Komenda S; Oulton A
    Neoplasma; 1997; 44(5):299-304. PubMed ID: 9473789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter.
    Hashimoto H; Sue Y; Saga Y; Tokumitsu M; Yachiku S
    Int J Urol; 2000 Dec; 7(12):457-63. PubMed ID: 11168685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia.
    Dellas A; Schultheiss E; Almendral AC; Gudat F; Oberholzer M; Feichter G; Moch H; Torhorst J
    Int J Cancer; 1997 Aug; 74(4):421-5. PubMed ID: 9291432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours.
    Kindblom LG; Ahldén M; Meis-Kindblom JM; Stenman G
    Virchows Arch; 1995; 427(1):19-26. PubMed ID: 7551341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.
    Ranuncolo SM; Varela M; Morandi A; Lastiri J; Christiansen S; Bal de Kier Joffé E; Pallotta MG; Puricelli L
    J Neurooncol; 2004 Jun; 68(2):113-21. PubMed ID: 15218947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis.
    Verstegen MJ; Leenstra DT; Ijlst-Keizers H; Bosch DA
    J Neurooncol; 2002 Jan; 56(1):21-8. PubMed ID: 11949823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Aug; 86(2):192-9. PubMed ID: 12144828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.